Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial
Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Lu Gan(Scholar Rock (United States)), Minal Barve(Mary Crowley Cancer Research Center), Stephen DeWall, Guru Sonpavde(AdventHealth Orlando), Mohammed Qatanani(Scholar Rock (United States)), Bruno Bockorny(Harvard University), Randy F. Sweis(University of Illinois Chicago), Justin F. Gainor(Harvard University), Deepak Kilari(Medical College of Wisconsin), Jing L. Marantz(Scholar Rock (United States)), Yawen Ju(Scholar Rock (United States)), Giridhar S. Tirucherai(Scholar Rock (United States)), Susan Henry(Scholar Rock (United States)), Ahmad A. Tarhini(Moffitt Cancer Center), Lan Liu(Scholar Rock (United States)), David Park(St. Jude Medical Center), Meredith McKean(Sarah Cannon), Ulka Vaishampayan(University of Michigan), Sunil Babu(Fort Wayne Medical Institute)
Cited by 2
Related Papers
Mechanisms of obesity-associated insulin resistance: many choices on the menu
|Genes & Development|2007|781
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
|Journal of Clinical Oncology|2011|686